InventisBio Co., Limited (SHA:688382)
China
· Delayed Price · Currency is CNY 22.19
-0.76 (-3.31%)
At close: Apr 28, 2026
InventisBio Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 37.29 | 168.79 | 185.53 | - | - | Upgrade
|
| Revenue Growth (YoY) | -77.91% | -9.02% | - | - | - | Upgrade
|
| Cost of Revenue | 5.02 | 3.92 | - | - | - | Upgrade
|
| Gross Profit | 32.27 | 164.87 | 185.53 | - | - | Upgrade
|
| Selling, General & Admin | 45.26 | 52.5 | 60.85 | 57.96 | 47.71 | Upgrade
|
| Research & Development | 325.79 | 384.35 | 442.91 | 461.49 | 315.04 | Upgrade
|
| Other Operating Expenses | 0.11 | 0.09 | 0.12 | -0 | 0.05 | Upgrade
|
| Operating Expenses | 383.76 | 445.82 | 513.18 | 519.44 | 362.8 | Upgrade
|
| Operating Income | -351.49 | -280.95 | -327.65 | -519.44 | -362.8 | Upgrade
|
| Interest Expense | -0.84 | -0.66 | -0.83 | -1.03 | -1.19 | Upgrade
|
| Interest & Investment Income | 25.89 | 30.02 | 40.45 | 17.38 | 12.76 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.39 | 1.56 | 1.18 | 19.99 | -11.33 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.11 | -0.11 | -0.27 | -0.2 | -0.21 | Upgrade
|
| EBT Excluding Unusual Items | -327.94 | -250.14 | -287.12 | -483.31 | -362.76 | Upgrade
|
| Gain (Loss) on Sale of Investments | 2.49 | 1.3 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.08 | - | - | 0 | Upgrade
|
| Other Unusual Items | 8.82 | 8.57 | 3.15 | -0.18 | 4.85 | Upgrade
|
| Pretax Income | -316.63 | -240.2 | -283.98 | -483.49 | -357.91 | Upgrade
|
| Income Tax Expense | 0.24 | - | - | - | - | Upgrade
|
| Net Income | -316.87 | -240.2 | -283.98 | -483.49 | -357.91 | Upgrade
|
| Net Income to Common | -316.87 | -240.2 | -283.98 | -483.49 | -357.91 | Upgrade
|
| Shares Outstanding (Basic) | 576 | 572 | 575 | 509 | 459 | Upgrade
|
| Shares Outstanding (Diluted) | 576 | 572 | 575 | 509 | 459 | Upgrade
|
| Shares Change (YoY) | 0.73% | -0.53% | 12.97% | 10.91% | -0.25% | Upgrade
|
| EPS (Basic) | -0.55 | -0.42 | -0.49 | -0.95 | -0.78 | Upgrade
|
| EPS (Diluted) | -0.55 | -0.42 | -0.49 | -0.95 | -0.78 | Upgrade
|
| Free Cash Flow | -162.36 | -249.53 | -314.04 | -484.59 | -278.59 | Upgrade
|
| Free Cash Flow Per Share | -0.28 | -0.44 | -0.55 | -0.95 | -0.61 | Upgrade
|
| Gross Margin | 86.54% | 97.67% | 100.00% | - | - | Upgrade
|
| Operating Margin | -942.59% | -166.45% | -176.61% | - | - | Upgrade
|
| Profit Margin | -849.74% | -142.31% | -153.06% | - | - | Upgrade
|
| Free Cash Flow Margin | -435.41% | -147.84% | -169.27% | - | - | Upgrade
|
| EBITDA | -346.58 | -275.16 | -322.31 | -514.77 | -360.15 | Upgrade
|
| EBITDA Margin | - | -163.02% | -173.73% | - | - | Upgrade
|
| D&A For EBITDA | 4.9 | 5.79 | 5.34 | 4.68 | 2.64 | Upgrade
|
| EBIT | -351.49 | -280.95 | -327.65 | -519.44 | -362.8 | Upgrade
|
| EBIT Margin | - | -166.45% | -176.61% | - | - | Upgrade
|
| Revenue as Reported | 37.29 | 168.79 | 185.53 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.